qtr-three adjusted non-gaap earnings per share $num-one.
qtr-three revenue $num-three billion versus refinitiv ibes estimate of $num-one billion.
for qtr-four year-six, company anticipates that non-gaap core revenue growth will be in low-to-mid teens percent range.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-one%.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-two%.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-one%.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-two%.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-three%.
for full year year-six, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than num-one%.